Compare FORM & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | CNTA |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | 2002 | 2021 |
| Metric | FORM | CNTA |
|---|---|---|
| Price | $124.82 | $39.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $98.25 | $43.17 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $499.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.00 | $10.95 |
| 52 Week High | $159.09 | $40.26 |
| Indicator | FORM | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 70.14 |
| Support Level | $112.31 | $39.36 |
| Resistance Level | $158.36 | $39.86 |
| Average True Range (ATR) | 9.85 | 0.09 |
| MACD | -1.16 | -0.19 |
| Stochastic Oscillator | 26.91 | 67.19 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.